This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

4SC-207

4SC AG

Drug Names(s): 4SC-207

Description: 4SC-207 is a novel, orally available cell-cycle blocker (CCB) for the treatment of tumours resistant to chemotherapy. This anti-mitotic compound inhibits the division of actively proliferating tumour cells. In preclinical testing, apoptosis was observed in dividing cancer cells only, rather than in non-proliferating cells.

4SC-207 News

Scrip R&D Head Ehlers Bows Out As Confidence In Biogen's Pipeline Suffers From Setbacks

Scrip Pipeline Watch: Phase III Starts With Evobrutinib, Gaboxadol

Pink Sheet FDA Performance Tracker: Breakthrough Therapy Designations

Scrip ENTRUST Bolsters Edoxaban As VKA Alternative In AF Patients

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug